2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Disparities Research, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5096 Epigenetic clock acceleration at diagnosis and end-of-induction minimal residual disease in pediatric B-cell acute lymphoblastic leukemia

Zuena Anbar Karim, BSA, Joshua David Strauss, MPH2, Michael Scheurer, MPH, PhD, FACE3, Karen R. Rabin, MD, PhD4, Philip J. Lupo, PhD, MPH5, Thanh Thien Hoang, PhD6
1 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States
2 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States
3 Emory University School of Medicine, Atlanta, Georgia, United States
4 University of San Francisco School of Medicine, San Francisco, California, United States
5 Emory University School of Medicine, Atlanta, Georgia, United States
6 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States
Background: Despite cure rates exceeding 90% at first diagnosis, relapse remains the leading cause of cancer-related death in children with B-cell acute lymphoblastic leukemia (B-ALL). End-of-induction (EOI) minimal residual disease (MRD) is a strong predictor of relapse, but it is only measurable after induction chemotherapy is complete. Whether biomarkers present at diagnosis may inform early treatment response is unknown. DNA methylation (DNAm)-based clocks summarize methylation patterns into quantitative measures of cellular proliferation history or biological aging and have been associated with survival outcomes in childhood ALL, but their relationship with EOI MRD has not been explored. We examined whether epigenetic clocks measured at diagnosis are associated with EOI MRD status in pediatric B-ALL. We hypothesized that higher epigenetic age acceleration at diagnosis would be associated with positive EOI MRD.

Methods: We evaluated 236 children (age 1-21) diagnosed with B-ALL treated at Texas Children’s Hospital between 2007 and 2024. Genome-wide DNAm data from diagnostic bone marrow samples were generated using the Illumina EPIC array and used to derive 11 epigenetic clocks: 6 mitotic/proliferation-related clocks (epiTOC1, epiTOC2.irS, RepliTali, HypoClock, EpiCMIT-Hyper, EpiCMIT-Hypo) and 5 principal component (PC)-based biological aging clocks (PCHorvath1, PCHorvath2, PCHannum, PCPhenoAge, PCGrimAge). For each clock, age acceleration, an age-adjusted residual, was derived by regressing the clock estimate on chronological age. The primary outcome was EOI MRD status (positive vs negative based on a cutoff of 0.01% by flow cytometry). Acceleration was modeled in tertiles (T1, lowest; T2, middle; T3, highest), with T1 as the reference group and cutpoints derived from MRD-negative patients. Logistic regression was used to assess associations between tertiles of clock acceleration and MRD status, adjusting for initial white blood cell count (dichotomized at ≥50,000/μL), sex, race/ethnicity, age at diagnosis category, and estimated proportions of 11 blood cell types. 

Results: Among 236 patients, 64 (27%) were EOI MRD positive. The median age at diagnosis was 6 years [IQR 3-11]; 56% were male, and 58% were Hispanic. Associations with MRD status were observed with 2 mitotic clocks and 1 biological aging clock. Compared with T1, RepliTali acceleration was associated with lower odds of MRD positivity in T2 (adjusted odds ratio [aOR], 0.41; 95% CI, 0.16-0.99; p=0.05) and in T3 (aOR, 0.36; 95% CI, 0.14-0.89; p=0.03). Positive associations were observed for EpiCMIT-Hypo in T2 (aOR, 1.82; 95% CI, 0.75-4.52) and PCGrimAge in T3 (aOR, 1.85; 95% CI, 0.73-4.83) but were not significant.

Conclusions: Overall, we found that RepliTali acceleration measured at B-ALL diagnosis showed an inverse association with EOI MRD positivity independent of clinical, demographic, and estimated cell-composition covariates, suggesting that lower mitotic clock values may relate to EOI MRD response. Positive but nonsignificant associations were observed for EpiCMIT-Hypo and PCGrimAge. DNAm-based clocks may reflect biological features related to early chemotherapy response and, if validated in independent cohorts, could serve as early biomarkers to provide predictive information at diagnosis in B-ALL.
Zuena Anbar Karim, BSA: No relevant conflicts of interest to declare.